Abstract
<p>Supplemental Figure 7: VAC treatment did not improve therapeutic efficacy of DOTA-EB-TATE in either low- or high-SSTR2 expressing tumors. (A) No effect of VAC on the tumor progression in the 177Lu-DOTA-EB-TATE treated FTC133 (low-SSTR2-expressing) subcutaneous xenograft mice model. C-control mice that received 177Lu-DOTA-EB-TATE (n=8); VAC-valproic acid treated mice that received 177Lu-DOTA-EB-TATE (n=9). Data are presented as mean{plus minus}SEM. (B) No effect of VAC on the tumor progression in the 177Lu-DOTA-EB-TATE treated AR42J (high-SSTR2-expressing) subcutaneous xenograft mice model. C-control mice that received 177Lu-DOTA-EB-TATE (n=8); VAC-valproic acid treated mice that received 177Lu-DOTA-EB-TATE (n=7). Data are presented as mean{plus minus}SEM.</p>
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
